Loading...
•
Mar 31, 2024
Xencor Q1 2024 Earnings Report
Reported financial results for the first quarter ended March 31, 2024.
Key Takeaways
Xencor reported a net loss of $68.0 million, or $(1.11) per share, for the first quarter ended March 31, 2024. Revenues for the quarter were $12.8 million, compared to $19.0 million for the same period in 2023. Cash, cash equivalents and marketable debt securities totaled $646.7 million as of March 31, 2024.
First patient dosed in Phase 1 study of XmAb®541 (CLDN6 x CD3) for CLDN6-positive tumors.
FDA approved Ultomiris® (Alexion Pharmaceuticals, Inc.) for adults with NMOSD.
Single dose of investigational antibody with Xtend™ confers protection against malaria infection.
Bart Cornelissen was appointed as Xencor’s senior vice president and chief financial officer.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Xencor expects to end 2024 with between $475 million and $525 million in cash, cash equivalents and marketable debt securities, and to have cash to fund research and development programs and operations into 2027.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...